Free Trial

AlloVir (ALVR) Competitors

AlloVir logo
$3.89 -0.39 (-9.11%)
As of 09/12/2025

ALVR vs. MEIP, STTK, CRVO, ALTS, ANEB, ENTX, KLRS, CRDL, OVID, and VXRT

Should you be buying AlloVir stock or one of its competitors? The main competitors of AlloVir include MEI Pharma (MEIP), Shattuck Labs (STTK), CervoMed (CRVO), ALT5 Sigma (ALTS), Anebulo Pharmaceuticals (ANEB), Entera Bio (ENTX), Kalaris Therapeutics (KLRS), Cardiol Therapeutics (CRDL), Ovid Therapeutics (OVID), and Vaxart (VXRT). These companies are all part of the "pharmaceutical products" industry.

AlloVir vs. Its Competitors

MEI Pharma (NASDAQ:MEIP) and AlloVir (NASDAQ:ALVR) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, institutional ownership, analyst recommendations, risk, earnings and profitability.

52.4% of MEI Pharma shares are held by institutional investors. Comparatively, 66.1% of AlloVir shares are held by institutional investors. 3.1% of MEI Pharma shares are held by company insiders. Comparatively, 32.1% of AlloVir shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, MEI Pharma had 5 more articles in the media than AlloVir. MarketBeat recorded 5 mentions for MEI Pharma and 0 mentions for AlloVir. MEI Pharma's average media sentiment score of 0.19 beat AlloVir's score of 0.00 indicating that MEI Pharma is being referred to more favorably in the media.

Company Overall Sentiment
MEI Pharma Neutral
AlloVir Neutral

MEI Pharma has a beta of 0.38, meaning that its share price is 62% less volatile than the S&P 500. Comparatively, AlloVir has a beta of 0.63, meaning that its share price is 37% less volatile than the S&P 500.

MEI Pharma is trading at a lower price-to-earnings ratio than AlloVir, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MEI PharmaN/AN/A$17.78M-$4.75-0.67
AlloVirN/AN/A-$190.42M-$20.23-0.19

AlloVir's return on equity of -71.03% beat MEI Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
MEI PharmaN/A -77.00% -64.79%
AlloVir N/A -71.03%-61.27%

Summary

AlloVir beats MEI Pharma on 6 of the 10 factors compared between the two stocks.

Get AlloVir News Delivered to You Automatically

Sign up to receive the latest news and ratings for ALVR and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ALVR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ALVR vs. The Competition

MetricAlloVirBiological Products IndustryMedical SectorNASDAQ Exchange
Market Cap$19.62M$289.72M$5.78B$10.18B
Dividend YieldN/AN/A5.73%4.60%
P/E Ratio-0.19N/A75.4626.02
Price / SalesN/A420.31466.1392.34
Price / CashN/A22.4425.8129.91
Price / Book0.1310.9112.166.25
Net Income-$190.42M-$111.61M$3.29B$270.76M
7 Day Performance-15.80%-0.50%0.74%3.87%
1 Month Performance70.61%4.64%5.00%5.49%
1 Year Performance-77.52%-15.57%62.55%25.86%

AlloVir Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ALVR
AlloVir
N/A$3.89
-9.1%
N/A-77.5%$19.62MN/A-0.19110Gap Down
High Trading Volume
MEIP
MEI Pharma
0.9684 of 5 stars
$2.84
-5.5%
N/A+3.5%$92.93MN/A-0.60100Upcoming Earnings
Gap Up
High Trading Volume
STTK
Shattuck Labs
3.909 of 5 stars
$1.94
+3.1%
$4.00
+106.3%
-49.6%$92.93M$5.72M-1.60100News Coverage
Analyst Upgrade
Short Interest ↓
Analyst Revision
CRVO
CervoMed
3.8153 of 5 stars
$9.94
-0.6%
$19.29
+94.1%
-49.5%$91.90M$9.74M-3.814Positive News
Analyst Revision
ALTS
ALT5 Sigma
0.1925 of 5 stars
$4.17
+0.8%
N/A+91.7%$89.79M$22.26M0.00170Short Interest ↑
ANEB
Anebulo Pharmaceuticals
2.1258 of 5 stars
$2.19
-0.7%
$5.50
+151.7%
+13.9%$89.76MN/A-8.404News Coverage
Gap Up
ENTX
Entera Bio
1.5009 of 5 stars
$1.95
-2.8%
$10.00
+414.1%
-9.5%$88.81M$180K-7.4820Positive News
KLRS
Kalaris Therapeutics
1.8598 of 5 stars
$4.69
+1.1%
$3.00
-36.0%
N/A$87.70MN/A0.00110News Coverage
Gap Down
CRDL
Cardiol Therapeutics
2.3147 of 5 stars
$1.05
-0.5%
$8.00
+665.6%
-56.9%$87.48MN/A-3.0720Short Interest ↑
OVID
Ovid Therapeutics
4.5339 of 5 stars
$1.25
+0.4%
$3.10
+149.0%
+5.9%$87.11M$570K-2.3160Positive News
VXRT
Vaxart
2.0287 of 5 stars
$0.38
-1.4%
$2.00
+427.0%
-60.5%$86.88M$47.40M-1.41120Gap Down

Related Companies and Tools


This page (NASDAQ:ALVR) was last updated on 9/14/2025 by MarketBeat.com Staff
From Our Partners